{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T17:02:19Z","timestamp":1788109339888,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40121-025-01121-6","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T23:06:07Z","timestamp":1743721567000},"page":"991-1010","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Five-Year Immune Persistence of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) and Immunogenicity and Safety of a Booster Dose in Children"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04936685","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Federico","family":"Martin\u00f3n-Torres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Simko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"R\u00e4met","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Zocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Syrkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siham","family":"Bchir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bertrand-Gerentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"1121_CR1","unstructured":"European Centre for Disease Prevention and Control. Invasive meningococcal disease - Annual Epidemiological Report for 2022. Stockholm; 2024."},{"key":"1121_CR2","unstructured":"US Centers for Disease Control and Prevention. Clinical overview of meningococcal disease. https:\/\/www.cdc.gov\/meningococcal\/hcp\/clinical\/index.html. Accessed 30 Jan 2025."},{"key":"1121_CR3","unstructured":"World Health Organization. Meningitis. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/meningitis. Accessed 30 Jan 2025."},{"issue":"8","key":"1121_CR4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S1474-4422(23)00195-3","volume":"22","author":"GBD 2019 Meningitis and Antimicrobial Resistance Collaborators","year":"2023","unstructured":"GBD 2019 Meningitis and Antimicrobial Resistance Collaborators. Global, regional, and national burden of meningitis and its aetiologies, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet Neurol. 2023;22(8):685\u2013711. https:\/\/doi.org\/10.1016\/S1474-4422(23)00195-3.","journal-title":"Lancet Neurol"},{"issue":"21","key":"1121_CR5","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1016\/j.vaccine.2019.04.020","volume":"37","author":"B Wang","year":"2019","unstructured":"Wang B, Santoreneos R, Giles L, Haji Ali Afzali H, Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37(21):2768\u201382. https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.020.","journal-title":"Vaccine"},{"key":"1121_CR6","unstructured":"European Centre for Disease Prevention and Control. Factsheet about meningococcal disease. https:\/\/www.ecdc.europa.eu\/en\/meningococcal-disease\/factsheet."},{"key":"1121_CR7","unstructured":"McNamara ABA. Meningococcal - Vaccine Preventable Diseases Surveillance Manual | CDC. 2022, https:\/\/www.cdc.gov\/vaccines\/pubs\/surv-manual\/chpt08-mening.html."},{"key":"1121_CR8","unstructured":"European Centre for Disease Prevention and Control. Vaccine scheduler; Meningococcal disease: recommended vaccinations. https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=48&SelectedCountryIdByDisease=-1. Accessed 30 Jan 2025."},{"issue":"2","key":"1121_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/20477724.2021.1972663","volume":"116","author":"F Martin\u00f3n-Torres","year":"2022","unstructured":"Martin\u00f3n-Torres F, Taha MK, Knuf M, et al. Evolving strategies for meningococcal vaccination in Europe: overview and key determinants for current and future considerations. Pathog Glob Health. 2022;116(2):85\u201398. https:\/\/doi.org\/10.1080\/20477724.2021.1972663.","journal-title":"Pathog Glob Health"},{"key":"1121_CR10","unstructured":"European Medicines Agency. MenQuadfi. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/menquadfi."},{"key":"1121_CR11","unstructured":"US Food and Drug Administration. MenQuadfi | FDA. https:\/\/www.fda.gov\/vaccines-blood-biologics\/menquadfi. Accessed 10 Jan 2025."},{"issue":"1","key":"1121_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2021.1902701","volume":"18","author":"FM Piazza","year":"2021","unstructured":"Piazza FM, Virta M, Paassilta M, et al. Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: a phase III, open-label, multi-center study. Hum Vaccin Immunother. 2021;18(1):1\u201310. https:\/\/doi.org\/10.1080\/21645515.2021.1902701.","journal-title":"Hum Vaccin Immunother"},{"key":"1121_CR13","doi-asserted-by":"publisher","DOI":"10.1017\/s0950268821000261","volume":"149","author":"D van der Vliet","year":"2021","unstructured":"van der Vliet D, Vesikari T, Sandner B, et al. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-na\u00efve and meningococcal C conjugate vaccine-primed toddlers: a phase III randomised study. Epidemiol Infect. 2021;149: e50. https:\/\/doi.org\/10.1017\/s0950268821000261.","journal-title":"Epidemiol Infect"},{"issue":"1","key":"1121_CR14","doi-asserted-by":"publisher","first-page":"2160600","DOI":"10.1080\/21645515.2022.2160600","volume":"19","author":"CA Robertson","year":"2023","unstructured":"Robertson CA, Jacqmein J, Selmani A, Galarza K, Oster P. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged \u226559 years: a phase III randomized study. Hum Vaccin Immunother. 2023;19(1):2160600. https:\/\/doi.org\/10.1080\/21645515.2022.2160600.","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"1121_CR15","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41390-023-02478-5","volume":"94","author":"B Zambrano","year":"2023","unstructured":"Zambrano B, Peterson J, Deseda C, et al. Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study. Pediatr Res. 2023;94(3):1035\u201343. https:\/\/doi.org\/10.1038\/s41390-023-02478-5.","journal-title":"Pediatr Res"},{"key":"1121_CR16","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/B978-1-4557-0090-5.00029-X","volume-title":"Vaccines","author":"DM Granoff","year":"2013","unstructured":"Granoff DM, Pelton S, Harrison LH. Meningococcal vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. London: W.B. Saunders; 2013. p. 388\u2013418. https:\/\/doi.org\/10.1016\/B978-1-4557-0090-5.00029-X.","edition":"6"},{"issue":"6","key":"1121_CR17","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1080\/21645515.2020.1733869","volume":"16","author":"T Vesikari","year":"2020","unstructured":"Vesikari T, Borrow R, Forsten A, Findlow H, Dhingra MS, Jordanov E. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a phase II randomized study. Hum Vaccin Immunother. 2020;16(6):1306\u201312. https:\/\/doi.org\/10.1080\/21645515.2020.1733869.","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"1121_CR18","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1080\/21645515.2020.1733867","volume":"16","author":"G \u00c1\u00f1ez","year":"2020","unstructured":"\u00c1\u00f1ez G, Hedrick J, Simon MW, et al. Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a phase III randomized study. Hum Vaccin Immunother. 2020;16(6):1292\u20138. https:\/\/doi.org\/10.1080\/21645515.2020.1733867.","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"1121_CR19","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1080\/21645515.2020.1746110","volume":"16","author":"T Vesikari","year":"2020","unstructured":"Vesikari T, Peyrani P, Webber C, et al. Ten-year antibody persistence and booster response to MenACWY-TT vaccine after primary vaccination at 1\u201310 years of age. Hum Vaccin Immunother. 2020;16(6):1280\u201391. https:\/\/doi.org\/10.1080\/21645515.2020.1746110.","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"1121_CR20","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1080\/21645515.2015.1136040","volume":"12","author":"R Baxter","year":"2016","unstructured":"Baxter R, Keshavan P, Welsch JA, Han L, Smolenov I. Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants. Hum Vaccin Immunother. 2016;12(5):1300\u201310. https:\/\/doi.org\/10.1080\/21645515.2015.1136040.","journal-title":"Hum Vaccin Immunother"},{"issue":"32","key":"1121_CR21","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1016\/j.vaccine.2005.03.045","volume":"23","author":"A Larrauri","year":"2005","unstructured":"Larrauri A, Cano R, Garc\u00eda M, Mateo SD. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine. 2005;23(32):4097\u2013100. https:\/\/doi.org\/10.1016\/j.vaccine.2005.03.045.","journal-title":"Vaccine"},{"issue":"10","key":"1121_CR22","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/archpedi.159.10.907","volume":"159","author":"H Keyserling","year":"2005","unstructured":"Keyserling H, Papa T, Koranyi K, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med. 2005;159(10):907\u201313. https:\/\/doi.org\/10.1001\/archpedi.159.10.907.","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"6","key":"1121_CR23","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.jpeds.2014.02.025","volume":"164","author":"R Baxter","year":"2014","unstructured":"Baxter R, Reisinger K, Block SL, Izu A, Odrljin T, Dull P. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents. J Pediatr. 2014;164(6):1409-15.e4. https:\/\/doi.org\/10.1016\/j.jpeds.2014.02.025.","journal-title":"J Pediatr"},{"issue":"17","key":"1121_CR24","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s40265-017-0828-8","volume":"77","author":"S Dhillon","year":"2017","unstructured":"Dhillon S, Pace D. Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT; Nimenrix\u00ae): a review. Drugs. 2017;77(17):1881\u201396. https:\/\/doi.org\/10.1007\/s40265-017-0828-8.","journal-title":"Drugs"},{"issue":"11","key":"1121_CR25","doi-asserted-by":"publisher","first-page":"881","DOI":"10.4161\/hv.6.11.12849","volume":"6","author":"CJ Gill","year":"2010","unstructured":"Gill CJ, Baxter R, Anemona A, Ciavarro G, Dull P. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo\u00ae) or Menactra\u00ae among healthy adolescents. Hum Vaccin. 2010;6(11):881\u20137. https:\/\/doi.org\/10.4161\/hv.6.11.12849.","journal-title":"Hum Vaccin"},{"issue":"12","key":"1121_CR26","doi-asserted-by":"publisher","first-page":"e298","DOI":"10.1097\/inf.0000000000000897","volume":"34","author":"T Vesikari","year":"2015","unstructured":"Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM. Immunogenicity, safety and antibody persistence of a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine compared with monovalent meningococcal serogroup C vaccine administered four years after primary vaccination using the same vaccines. Pediatr Infect Dis J. 2015;34(12):e298-307. https:\/\/doi.org\/10.1097\/inf.0000000000000897.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"1121_CR27","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1080\/21645515.2015.1058457","volume":"12","author":"T Vesikari","year":"2016","unstructured":"Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM. Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine. Hum Vaccin Immunother. 2016;12(1):132\u20139. https:\/\/doi.org\/10.1080\/21645515.2015.1058457.","journal-title":"Hum Vaccin Immunother"},{"issue":"suppl_1","key":"1121_CR28","doi-asserted-by":"publisher","first-page":"S319","DOI":"10.1093\/ofid\/ofu052.793","volume":"1","author":"NP Klein","year":"2014","unstructured":"Klein NP, Block SL, Johnston W, et al. Persistence of meningococcal bactericidal antibodies and booster response at 60-months of age in children who received infant or toddler doses of MenACWY-CRM conjugate vaccine. Open Forum Infect Dis. 2014;1(suppl_1):S319. https:\/\/doi.org\/10.1093\/ofid\/ofu052.793.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"1121_CR29","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1080\/21645515.2018.1532248","volume":"15","author":"R Booy","year":"2019","unstructured":"Booy R, Gentile A, Nissen M, Whelan J, Abitbol V. Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies. Hum Vaccin Immunother. 2019;15(2):470\u201380. https:\/\/doi.org\/10.1080\/21645515.2018.1532248.","journal-title":"Hum Vaccin Immunother"},{"key":"1121_CR30","unstructured":"European Centre for Disease Prevention and Control. Cases of invasive meningococcal disease reported in travellers returning from the Kingdom of Saudi Arabia. https:\/\/www.ecdc.europa.eu\/en\/news-events\/cases-invasive-meningococcal-disease-reported-travellers-returning-kingdom-saudi-arabia. Accessed 04 Sept 2024."},{"issue":"22","key":"1121_CR31","doi-asserted-by":"publisher","first-page":"514","DOI":"10.15585\/mmwr.mm7322e1","volume":"73","author":"MS Vachon","year":"2024","unstructured":"Vachon MS, Barret AS, Lucidarme J, et al. Cases of meningococcal disease associated with travel to Saudi Arabia for Umrah pilgrimage: United States, United Kingdom, and France, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(22):514\u20136. https:\/\/doi.org\/10.15585\/mmwr.mm7322e1.","journal-title":"MMWR Morb Mortal Wkly Rep"}],"updated-by":[{"DOI":"10.1007\/s40121-026-01426-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000}}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01121-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01121-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01121-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T05:39:31Z","timestamp":1787204371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01121-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1121"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01121-6","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: Figure 4 has been updated","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40121-026-01426-0","URL":"https:\/\/doi.org\/10.1007\/s40121-026-01426-0","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C\u00e9line Zocchetti, Olga Syrkina, Siham Bchir and Isabelle Bertrand-Gerentes are employees of Sanofi and may hold shares and\/or stock options in the company. Mika R\u00e4met: Finnish Vaccine Research Ltd. (formerly Tampere University Vaccine Research Center) carries out clinical vaccine trials sponsored by all major vaccine manufacturers including Sanofi. Rolf Ebert has no conflicts of interest to disclose. Robert Simko: Scientific lecture fees from Sanofi. Federico Martin\u00f3n-Torres: Acted as principal investigator in randomized controlled trials of Ablynx, Abbot, Seqirus, Sanofi Pasteur MSD, Sanofi Pasteur, Cubist, Wyeth, Merck, Pfizer, Roche, Regeneron, Jansen, Medimmune, Moderna, Novavax, Novartis, and GSK, with honoraria paid to his institution. FM-T also reports consulting or advisory relationships with GSK Vaccines SRL, Pfizer Inc, Sanofi Pasteur Inc, Janssen Pharmaceuticals Inc, Moderna, MSD, and Seqirus Pty Ltd.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the protocol and consensus ethical principles derived from international guidelines, including the Declaration of Helsinki, the International Council for Harmonisation guidelines for Good Clinical Practice, and all applicable laws, rules, and regulations. The study protocol, informed consent form, and investigator\u2019s brochure were reviewed and approved by the Independent Ethics Committee (IEC) and\/or Investigational Review Board (IRB) for each study site before the study was initiated. The IECs\/IRBs for all study centers are listed in the supplementary materials (Supplementary Table\u00a01). Parents or other legally acceptable representatives of participants were required to sign a statement of informed consent.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}